Pharmaceutical preparations

JP2024505630A5Active Publication Date: 2024-12-04REDX PHARMA PLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023542980
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-01-15
Filing Date
2022-01-14
Publication Date
2024-12-04
Estimated Expiration
2042-01-14

AI Technical Summary

Technical Problem

Conventional pharmaceutical formulations of Compound I face challenges in achieving uniformity and content uniformity at lower active ingredient contents, particularly at doses of 0.5 mg and 1.0 mg per capsule, making it difficult to meet the requirements for uniformity of dosage units and stability.

Method used

A semi-solid diluent, such as vitamin E polyethylene glycol succinate or Gelucire®, is used to disperse Compound I, forming a semi-solid pharmaceutical formulation that can be encapsulated in gelatin capsules, ensuring uniformity and stability at low doses.

Benefits of technology

The semi-solid formulation achieves uniform active ingredient content within a batch and from capsule to capsule, meeting the requirements for uniformity and stability, as demonstrated by HPLC analysis, and is suitable for treating various cancers and diseases modulated by Porcn.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2022153062000001
    Figure 2022153062000001
Patent Text Reader

Abstract

The present invention relates to pharmaceutical formulations and methods for preparing pharmaceutical formulations. In particular, the present invention relates to pharmaceutical formulations and methods for preparing pharmaceutical formulations comprising Compound I and a diluent.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to pharmaceutical formulations and methods for preparing pharmaceutical formulations. In particular, the present invention relates to pharmaceutical formulations and methods for preparing pharmaceutical formulations comprising Compound I and a diluent.

[0002] The pharmaceutical preparations of the present invention can be used to treat diseases mediated by the Wnt signaling pathway, such as cancer, for example biliary tract cancer, or to enhance the efficacy of anti-cancer treatments.

[0003] The described invention provides pharmaceutical formulations proposed to inhibit Wnt-mediated signaling, including paracrine signaling in tissues surrounding the tumor and autocrine and paracrine signaling in cancer cells. [Background technology]

[0004] Wnt genes encode a large and highly conserved family of secreted growth factors. During normal development, transcription of Wnt family genes is tightly controlled in time and space. To date, 19 Wnt proteins have been discovered in humans. All Wnt proteins are cysteine-rich glycoproteins of 38-43 kDa. Wnts play various roles in controlling cell fate, migration, proliferation and death during development. In adults, the role of Wnts is thought to be related to the maintenance of tissue homeostasis through aberrant signaling that is implicated in various cancers.

[0005] Wnt proteins undergo post-translational modifications that have been shown in several mutational experiments to be essential for effective protein trafficking and secretion (Tang, et al. (2012) Dev. Biol 364, 32-41; Takada, R. et al (2006) Dev. Cell 11, 791-801). Palmitoylation of Wnt proteins occurs at several conserved amino acids (C77, S209) and is carried out by porcupine, an O-acetyltransferase in the endoplasmic reticulum. Mutations in porcupine have been shown to cause developmental disorders, including focal dermal hypoplasia, through impaired Wnt pathway signaling (Grzeschik, et al. (2007) Nat. Genet, 39 pp.833-835). The dependency of Wnt ligand signaling on porcupine, and a body of evidence linking Wnt pathway signaling to cancer, have identified porcupine as a potential anticancer target.

[0006] WO2016 / 055786 relates to novel small molecule porcupine inhibitors (PORCN) that prevent wingless-type MMTV Integration Site (Wnt) ligand secretion and downstream activation of the pathway. The disclosed compounds have been shown to have activity in relevant ring finger protein 43 (RNF43) mutant cancer models both in vitro and in vivo, demonstrating therapeutic margins in vivo. RNF43 mutations are known to occur in both gastric and pancreatic cancer. Furthermore, preclinical evidence suggests that biliary tract cancer patients are sensitive to PORCN inhibition due to their high Wnt ligand drive.

[0007] The present invention relates to formulations of a particular compound of WO2016 / 055786 (herein referred to as Compound I). Summary of the Invention [Problem to be solved by the invention]

[0008] Previously, pharmaceutical formulations of Compound I have been prepared as solid blend formulations containing the drug substance at active ingredient contents of 5.0 mg, 10.0 mg, 20.0 mg, and 40.0 mg, with the drug substance mixed with conventional excipients for such formulations. However, it has since been found that lower active ingredient contents are required; specifically, dosages of 0.5 mg and 1.0 mg per capsule are required. It is difficult to achieve the capsule uniformity and content uniformity required at the lower active ingredient contents of solid blend formulations using conventional manufacturing approaches.

[0009] It is an object of certain embodiments of the present invention to provide pharmaceutical formulations comprising an effective dose of Compound I. It is an object of certain embodiments of the present invention to provide pharmaceutical formulations comprising a low dose of Compound I, e.g., a lower active ingredient content than that described in certain clinical studies.

[0010] It is an object of certain embodiments of the present invention to provide a method for preparing a pharmaceutical formulation comprising compound I.

[0011] It is an object of certain embodiments of the present invention to provide a method for producing a pharmaceutical formulation comprising Compound I that is uniform at a low dose. It is an object of certain embodiments of the present invention to provide a method for producing a pharmaceutical formulation comprising Compound I that is uniform at a low dose within a batch, which complies with the requirements for uniformity of dosage units (uniformity of content) as described in the relevant pharmacopoeias, for example, section 2.9.40 of the European Pharmacopoeia. It is an object of certain embodiments of the present invention to provide a method for producing a pharmaceutical formulation comprising Compound I that has a consistent active ingredient content between capsules compared to Compound I at a low dose, both in the average and in the individual dosage units, demonstrating an active drug content in the range of 90-110% of the label claim as measured by HPLC analysis.

[0012] It is an object of certain embodiments of the present invention to provide a method for preparing a stable pharmaceutical formulation containing Compound I that is homogeneous at a low dose.

[0013] Certain embodiments of the present invention meet some or all of the above objectives. [Means for solving the problem]

[0014] A brief summary of disclosures According to a first aspect of the present invention, a compound I is provided dispersed in a semi-solid diluent: [ka] Compound I A semi-solid pharmaceutical formulation is provided comprising:

[0015] By combining Compound I with a semi-solid diluent, the inventors have discovered that they can achieve the desired uniformity of API (active pharmaceutical ingredient) in the formulation. The resulting formulation can be encapsulated. For example, gelatin capsules can be used. The capsule can then be administered to a patient in need.

[0016] The semi-solid diluent may be an amphiphilic agent in which a polyalkylene glycol, e.g., polyethylene glycol, is bonded to a lipophilic or hydrophobic molecular entity. The polyethylene glycol chain may contain 3 to 70 alkylene glycol (e.g., ethylene glycol) units. Semi-solid formulations formed using these diluents are particularly beneficial in achieving stable formulations.

[0017] The melting point of the semi-solid diluent may be in the range of 40° C. to 55° C., such as 42° C. to 51° C. The theoretical HLB (hydrophilic lipophilic balance, i.e., the degree to which a component is hydrophilic or lipophilic) of the semi-solid diluent may be in the range of 10 to 20, such as 12 to 17.

[0018] In some embodiments, the semi-solid formulation comprises a Gelucire® component. The name Gelucire® is followed by a set of two numbers: the first value (e.g., 44) indicates the melting point in degrees Celsius, and the second value (e.g., 14) indicates the theoretical HLB (hydrophilic lipophilic balance), i.e., the degree to which the component is hydrophilic or lipophilic. The melting point of a Gelucire® component may be in the range of 40° C. to 55° C., e.g., 42° C. to 51° C., e.g., 44° C., 48° C. or 50° C. The theoretical HLB may be in the range of 1 to 20, e.g., 12 to 17, e.g., 01, 13, 14 or 16.

[0019] In some embodiments, the semi-solid diluent is selected from the group comprising polyethylene glycols, e.g., PEG (e.g., PEG 1000 or higher Mw variants), water-soluble surfactants, e.g., Gelucire® 48 / 16, water-dispersible surfactants, e.g., Gelucire® 44 / 14 or Gelucire® 50 / 13, or hard fats, e.g., Gelucire® 43 / 01, Vitamin E polyethylene glycol succinate (TPGS), polyoxyl 35 castor oil, e.g., Kolliphor EL, polyoxyl 40 castor oil, e.g., Kolliphor RH40, Solutol HS15 (polyoxyethylene ester of 12-monohydroxystearic acid), glyceryl stearate (Imwitor 900), capric / caprylic glyceryl esters such as Capmul MCM. In some embodiments, the semi-solid diluent is selected from the group including water soluble surfactants, water dispersible surfactants, hard fats, vitamin E polyethylene glycol succinate, medium chain triglycerides, polyoxyl 35 castor oil.

[0020] In some embodiments, the semi-solid diluent is selected from the group including vitamin E polyethylene glycol succinate and lauroyl macrogol-32 glyceride. Thus, in some embodiments, the semi-solid diluent is vitamin E polyethylene glycol succinate. Thus, in some embodiments, the semi-solid diluent is a PEGylated lipid, for example, Gelucire® 44 / 14 (lauroyl macrogol-32 glyceride). In some embodiments, the semi-solid diluent is Gelucire® 48 / 16, (macrogol-32 stearate), Gelucire® 50 / 13 (stearoyl macrogol-32 glyceride) or Gelucire® 43 / 01 (hard fat). Gelucire® 48 / 16 is a polyethylene glycol monostearate (type I) NF, consisting of PEG-32 (MW1500) esters of palmitic acid (C16) and stearic acid (C18). It is solid at ambient temperature. Gelucire® 44 / 14 is a lauroyl polyoxyl / macrogol 32 glyceride NF / EP, consisting mainly of PEG-32 (MW 1500) mono- and diesters of lauric acid (C12) with small amounts of mono-, di- and triglycerides. Gelucire® 50 / 13 is a stearoyl polyoxyl / macrogol 32 glyceride NF / EP, consisting of mono-, di- and triglycerides and PEG-32 (MW 1500) mono- and diesters of palmitic acid (C16) and stearic acid (C18). Gelucire® 43 / 01 is composed of mono-, di- and triglyceride esters of fatty acids (C8-C18), with the triester moiety predominating.

[0021] Compound I is particularly compatible with vitamin E polyethylene glycol succinate and Gelucire® 44 / 14, a polyethylene glycol glyceride.

[0022] In some embodiments, the semi-solid pharmaceutical formulation further comprises an antioxidant. In some embodiments, the antioxidant can be selected from butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT).

[0023] In some embodiments, the semi-solid pharmaceutical formulation further comprises a pharma- ceutically acceptable excipient selected from the group including sodium lauryl sulfate, poloxamer, and other surfactants. In some embodiments, the semi-solid pharmaceutical formulation further comprises a polymeric agent, for example, a polymeric agent capable of inhibiting precipitation of Compound I. In some embodiments, the polymeric agent is selected from the group including polyvinylpyrrolidone (PVP), hydroxypropylmethylcellulose (HPMC), methylcellulose, and copovidone.

[0024] In some embodiments, the semi-solid pharmaceutical formulation comprises compound I in an amount of 0.1% w / w to about 10% w / w. In some embodiments, the semi-solid pharmaceutical formulation comprises compound I in an amount of 0.5% w / w to about 5% w / w. In some embodiments, the semi-solid pharmaceutical formulation comprises compound I in an amount of about 0.5% w / w, about 1% w / w, about 1.5% w / w, about 2% w / w, about 2.5% w / w, about 3% w / w, about 3.5% w / w, about 4% w / w, about 4.5% w / w, or about 5% w / w. In some embodiments, the semi-solid pharmaceutical formulation comprises compound I in an amount of 0.5% w / w to about 3% w / w. In some embodiments, the semi-solid pharmaceutical formulation comprises compound I in an amount of 1.5% w / w to about 2.5% w / w. In some embodiments, the semi-solid pharmaceutical formulation comprises compound I in an amount of 1% w / w to about 2% w / w.

[0025] In some embodiments, the semisolid pharmaceutical formulation comprises compound I at a total dose of about 0.05 mg to about 5 mg. In some embodiments, the semisolid pharmaceutical formulation comprises compound I at a total dose of about 0.25 mg to about 2.5 mg. In some embodiments, the semisolid pharmaceutical formulation comprises compound I at a total dose of about 0.25 mg to about 1.5 mg. In some embodiments, the semisolid pharmaceutical formulation comprises compound I at a total dose of about 0.25 mg, about 0.5 mg, about 0.75 mg, about 1.0 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2.0 mg, about 2.25 mg or about 2.5 mg. In some embodiments, the semisolid pharmaceutical formulation comprises compound I at a total dose of about 0.5 mg to about 1 mg.

[0026] In one embodiment, the semi-solid pharmaceutical formulation comprises: Compound I present in an amount of 0.5% w / w to 3% w / w; Vitamin E polyethylene glycol succinate in an amount of 97% w / w to 99.5% w / w. In one embodiment, the semi-solid pharmaceutical formulation comprises: Compound I present in an amount of 1% w / w to 2% w / w; Vitamin E polyethylene glycol succinate in an amount of 98% w / w to 99% w / w.

[0027] In some embodiments, the semi-solid pharmaceutical formulation is encapsulated in a capsule. In some embodiments, the capsule is a gelatin capsule. In some embodiments, the capsule is a plant-derived capsule, such as HPMC. In some embodiments, the semi-solid pharmaceutical formulation is encapsulated in a gelatin capsule, such as a milky white gelatin capsule (gelatin and titanium dioxide).

[0028] In one embodiment, the semi-solid pharmaceutical formulation comprises a total dose of about 0.5 mg to 2 mg of compound I and about 48.0 mg to about 49.5 mg of vitamin E polyethylene glycol succinate. In one embodiment, the semi-solid pharmaceutical formulation comprises a total dose of about 0.5 mg to 2 mg of compound I and about 48 mg to about 49.5 mg of vitamin E polyethylene glycol succinate encapsulated in a gelatin capsule.

[0029] In one embodiment, the semi-solid pharmaceutical formulation comprises a total dose of about 0.75 mg to 1.25 mg of compound I and about 48.75 mg to about 49.25 mg of vitamin E polyethylene glycol succinate. In one embodiment, the semi-solid pharmaceutical formulation comprises a total dose of about 0.75 mg to 1.25 mg of compound I and about 48.75 mg to about 49.25 mg of vitamin E polyethylene glycol succinate encapsulated in a gelatin capsule.

[0030] In one embodiment, the semi-solid pharmaceutical formulation comprises a total dose of about 0.25 mg to about 0.75 mg of compound I and about 49.25 mg to about 49.75 mg of vitamin E polyethylene glycol succinate. In one embodiment, the semi-solid pharmaceutical formulation comprises a total dose of about 0.25 mg to about 0.75 mg of compound I and about 49.25 mg to about 49.75 mg of vitamin E polyethylene glycol succinate encapsulated in a gelatin capsule.

[0031] In one embodiment, the semi-solid pharmaceutical formulation comprises a total dose of about 1 mg of compound I and about 49 mg of vitamin E polyethylene glycol succinate.In one embodiment, the semi-solid pharmaceutical formulation comprises a total dose of about 1 mg of compound I and about 49 mg of vitamin E polyethylene glycol succinate encapsulated in a gelatin capsule.

[0032] In one embodiment, the semi-solid pharmaceutical formulation comprises a total dose of about 0.5 mg of compound I and about 49.5 mg of vitamin E polyethylene glycol succinate. In one embodiment, the semi-solid pharmaceutical formulation comprises a total dose of about 0.5 mg of compound I and about 49.5 mg of vitamin E polyethylene glycol succinate encapsulated in a gelatin capsule.

[0033] The semi-solid pharmaceutical formulation of the present invention can be used for medical applications.

[0034] The semi-solid pharmaceutical formulation of the present invention can be used in the treatment of cancer.

[0035] The present invention also provides a method of treating cancer, the method comprising administering to a subject in need of treatment a therapeutically acceptable amount of the semi-solid formulation of the first aspect.

[0036] The cancer may be selected from sarcoma, melanoma, skin cancer, blood tumors, lymphoma, carcinoma, adenoma and leukemia. The specific cancers, sarcomas, melanomas, skin cancers, blood tumors, lymphomas, carcinomas and leukemias that may be treated by the compounds of the present invention may be selected from esophageal squamous cell carcinoma, gastric cancer, glioblastoma, astrocytoma; retinoblastoma, osteosarcoma, chondrosarcoma, Ewing's sarcoma, rhabdomyosarcoma, Wilms' tumor, basal cell carcinoma, non-small cell lung cancer, brain tumor, hormone refractory prostate cancer, prostate cancer, metastatic breast cancer, breast cancer, metastatic pancreatic cancer, pancreatic cancer, colorectal cancer, biliary tract cancer such as cholangiocarcinoma, thymic cancer, cervical cancer, head and neck squamous cell carcinoma and head and neck cancer.

[0037] The cancer may be a solid tumor. The cancer may be selected from gastric cancer, pancreatic cancer, colorectal cancer, thymic cancer, and biliary tract cancer, such as cholangiocarcinoma. The cancer may be selected from biliary tract cancer, such as colorectal cancer, thymic cancer, and bile duct cancer. The cancer may be selected from biliary tract cancer, such as colorectal cancer, pancreatic cancer, and bile duct cancer. The cancer may be biliary tract cancer, such as cholangiocarcinoma. The cancer may be thymic cancer. The cancer may be colorectal cancer. The cancer may be pancreatic cancer.

[0038] The semi-solid pharmaceutical formulation of the present invention may be for the treatment of diseases modulated by Porcn.

[0039] The present invention also provides a method for treating a disease regulated by Porcn, the method comprising administering to a subject in need of treatment a therapeutically acceptable amount of a semi-solid formulation of the first aspect.

[0040] The disease regulated by Porcn may be cancer.

[0041] The disease regulated by Porcn may be selected from skin fibrosis, idiopathic pulmonary fibrosis, renal interstitial fibrosis, hepatic fibrosis, proteinuria, renal transplant rejection, osteoarthritis, Parkinson's disease, cystoid macular edema, cystoid macular edema associated with uveitis, retinopathy, diabetic retinopathy and retinopathy of prematurity.

[0042] The semi-solid pharmaceutical formulation of the present invention may be used for the treatment of a disease selected from skin fibrosis, idiopathic pulmonary fibrosis, renal interstitial fibrosis, hepatic fibrosis, proteinuria, renal transplant rejection, osteoarthritis, Parkinson's disease, cystoid macular edema, cystoid macular edema associated with uveitis, retinopathy, diabetic retinopathy and retinopathy of prematurity.

[0043] The present invention also provides a method of treating a disease selected from skin fibrosis, idiopathic pulmonary fibrosis, renal interstitial fibrosis, hepatic fibrosis, proteinuria, renal transplant rejection, osteoarthritis, Parkinson's disease, cystoid macular edema, cystoid macular edema associated with uveitis, retinopathy, diabetic retinopathy and retinopathy of prematurity, the method comprising administering a therapeutically acceptable amount of the semi-solid formulation of the first aspect to a subject in need thereof.

[0044] According to a second aspect of the present invention, there is provided a method for producing a semi-solid pharmaceutical formulation, the method comprising the steps of: (i) melting a semi-solid diluent; (ii) dispersing Compound I in a molten semi-solid diluent to form a molten blend; (iii) filling the molten blend into capsule shells.

[0045] In some embodiments, the method of the second aspect may be used to provide the semi-solid pharmaceutical formulation of the first aspect and related embodiments.

[0046] In some embodiments, step (ii) comprises dissolving compound I in a semi-solid diluent. In some embodiments, step (ii) further comprises mixing compound I with the molten semi-solid diluent of step (i).

[0047] In some embodiments, the method may further comprise the step of passing Compound I through a sieve to remove lumps prior to the step of dissolving Compound I in the diluent.

[0048] In some embodiments, Compound I and the molten diluent are mixed continuously using a suitable mixer to produce a homogenous solution.

[0049] Capsule filling can be performed using conventional capsule filling methods and equipment suitable for use with molten semi-solid formulations. Capsules can be filled using a variety of methods that dispense a measured amount of formulation into the empty capsule shell. This can include manual filling methods using a positive displacement pipette or using an automated capsule filling machine. In an exemplary filling process, the body and cap of the capsule are separated and the body is secured using a capsule holder. For manual filling, a pipette is used to measure and dispense a known volume and weight of formulation into the capsule body. After filling is complete, the cap is replaced and manually secured to the capsule body. For filling using an automated system, commercially available machinery is used that accomplishes the equivalent function of manual filling.

[0050] In some embodiments, the melting of the semi-solid diluent is carried out at a temperature of about 30°C to about 90°C. In some embodiments, the melting of the semi-solid diluent is carried out at a temperature of about 40°C to about 80°C. In some embodiments, the melting of the semi-solid diluent is carried out at a temperature of about 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C or about 80°C. In some embodiments, the melting of the semi-solid diluent is carried out at a temperature of about 45°C to about 80°C. In some embodiments, the melting of the semi-solid diluent is carried out at a temperature of about 50°C to about 60°C. In some embodiments, the melting of the semi-solid diluent is carried out at a temperature of about 55°C.

[0051] Detailed Description Throughout the description and claims of this specification, the terms "comprise" and "contain" and variations thereof mean "including but not limited to" and are not intended to (and do not) exclude other moieties, additives, ingredients, integers or steps. Throughout the description and claims of this specification, the singular encompasses the plural unless the context requires otherwise. In particular, where the indefinite article is used, the specification should be understood as contemplating the plural as well as the singular, unless the context requires otherwise.

[0052] It should be understood that features, integers, properties, compounds, chemical moieties or groups described in connection with a particular aspect, embodiment or example of the invention are applicable to any other aspect, embodiment or example described herein, unless inconsistent therewith. All features disclosed herein (including the accompanying claims, abstract and drawings), and / or all steps of the method or process so disclosed, may be combined in any combination, except for combinations that are at least partially mutually exclusive of such features and / or steps. The invention is not limited to the details of the foregoing embodiments. The invention extends to any novel, any novel combination of features disclosed herein (including the accompanying claims, abstract and drawings), or any novel, any novel combination of steps of any method or process disclosed.

[0053] The term "semi-solid" refers to a material that has the properties of both a liquid and a solid at room temperature, i.e., a material that has a viscosity and stiffness intermediate between that of a solid and a liquid. At lower temperatures, the material may exhibit the properties of a solid. At higher temperatures, the material may exhibit the properties of a liquid. The term "semi-solid" may refer to a waxy solid that is a wax at room temperature but softens and / or melts at elevated temperatures.

[0054] The term "stable" refers to both chemical and physical stability. The term "stable" may refer to the chemical and / or physical stability of a compound or composition over a period of time (e.g., 6 months) at about 20°C to about 40°C and about 50% RH to about 80% RH. For example, the compound or composition may be chemically and / or physically stable for a period of 24 hours. The compound or composition may be chemically and / or physically stable for a period of up to 6 months. The compound or composition may be chemically and / or physically stable for a period of 12 months. The compound or composition may be chemically and / or physically stable for a period of up to 12 months. The compound or composition may be chemically and / or physically stable for a period of up to 24 months or up to 36 months. The composition may be physically and chemically stable at 40°C / 75% RH for 6 months. The composition may be physically and chemically stable at 25°C / 60% RH for 24 months.

[0055] The reader's attention is directed to all articles and documents related to this application that have been filed contemporaneously with or prior to this application and that are open to public inspection together with this application, and the contents of all such articles and documents are incorporated herein by reference. EXAMPLES

[0056] Example 1 Compound I can be prepared according to the procedures outlined in the general scheme of WO2016 / 055786. Alternatively, Compound I can be prepared according to the procedures outlined in Example 9 of WO2016 / 055786.

[0057] Experimental stability / excipient compatibility studies were performed to demonstrate that Compound I was compatible with Vitamin E polyethylene glycol succinate and gelatin capsule shells in prototype formulations at 25°C / 60% RH and 40°C / 75% RH over a period of more than one month. No significant degradation of Compound I was observed, so the combination of Compound I, Vitamin E polyethylene glycol succinate, and gelatin capsule shells was selected for use in capsules containing Compound I. Stability evaluation of the selected formulations to support the establishment of shelf life is reported in Example 2. Small-scale manufacturability studies also demonstrated that the formulation could be consistently filled into gelatin capsules to the required fill weight and provide acceptable assay and dose unit uniformity (content uniformity). A homogeneous solution of Compound I was formed in Vitamin E polyethylene glycol succinate (TPGS), which allows good content uniformity to be achieved at low active ingredient content.

[0058] Example 2 Compound I 0.5 mg and 1 mg capsules are manufactured from blends of drug substance at 1% w / w and 2% w / w concentrations, respectively, and mixed with excipients. The batch formulations of Compound I capsule blends for 500 g batch sizes are shown in Table 1 for two different capsule active ingredient contents. Compound I capsule blend batch sizes can be adjusted as needed to support the needs of clinical programs for prorated ingredients.

[0059] Table 1: Batch formulation of Compound I capsule blend [Table 1] *The amount of Compound I included in the formulation can be corrected for purity, water, and solvent. The concentration of Vitamin E polyethylene glycol succinate is also adjusted to maintain the same total blend weight.

[0060] Show me how Compound I capsules are manufactured from a mixture of drug substance and excipients according to the batch formulation listed in Table 1 using conventional mixing and capsule filling processes following good manufacturing practice. Vitamin E polyethylene glycol succinate is melted at a product temperature of 45°C or higher and 80°C or lower. Compound I is passed through a suitable size sieve (prescreen) if necessary to remove any lumps, and then added to the molten Vitamin E polyethylene glycol succinate. Both components are continuously mixed using a suitable mixer to produce a homogenous solution as confirmed by visual inspection. The appropriate amount of the molten blend is accurately transferred into the gelatin capsule shell to achieve the target capsule fill weight (see Table 2). In this example, the filling is performed manually, with the capsule body and cap being manually separated and the body being secured using a capsule holder. A known volume and weight of the molten formulation is injected into the capsule using a pipette, after which the cap and body are manually joined. The molten blend is continuously mixed at a temperature suitable to maintain the blend in a molten state as described above during the capsule filling process.

[0061] Table 2: Compound I Drug Ingredients [Table 2]

[0062] Compound I manufacturing process and management TIFF2024505630000005.tif74158 Samples are tested according to the following methods: The analytical procedures used for testing of Compound I in 0.5 mg and 1.0 mg capsules are outlined below. a) Appearance (AM003): Visual inspection of Compound I capsules reveals size #3 milky white capsules with no physical defects. b) Identity, Content Uniformity, Assay and Related Substances by UPLC (AM402): UHPLC reversed phase method is used for assay / related substances, content uniformity and identity testing of Compound I capsules and is suitable for testing 0.5 mg and 1.0 mg capsules. Details of the chromatographic conditions are shown in Table 3.

[0063] Table 3: UHPLC retention times of the compounds [Table 3]

[0064] Working standards (system suitability standards) are prepared in duplicate at 0.1 mg / mL in diluent for assay and at 0.02 mg / mL in diluent for content uniformity. Sensitivity standards are prepared by diluting the working standard to 0.1% and 0.05%. Content uniformity sample preparation: Prepare working sample solutions of all dose levels of active ingredient at 0.02 mg / mL. Assay / analog sample preparation: Prepare working sample solutions of all dose levels of active ingredient at 0.1 mg / mL in duplicate.

[0065] Batch analytical data for 0.5 mg and 1.0 mg capsules of Compound I are shown in Table 4.

[0066] Table 4: Batch analytical data for 0.5 mg and 1.0 mg capsules of Compound I [Table 4] The pharmaceutical products listed in Table 2 have been shown to be physically and chemically stable for 6 months at 40°C / 75% RH and 24 months at 25°C / 60% RH.

[0067] The drugs listed in Table 2 have been administered to patients in Phase I clinical studies targeting adult advanced solid tumors (e.g., colorectal, biliary tract, and thymic cancers). Pharmacokinetic studies have demonstrated that the drugs listed in Table 2 promote good absorption and adequate exposure of the drug. Furthermore, preliminary clinical efficacy has been observed in some patients with potential Wnt ligand-dependent bile duct, colorectal, and thymic tumors.

[0068] Example 3 Four batches of Compound I, two each of 0.5 mg and 1.0 mg capsules, have been set up in accelerated, intermediate and long-term storage evaluations to support shelf-life determinations that may allow further extension of shelf-life.

[0069] Table 5: Determination of quality shelf life [Table 5] The samples were tested according to the methods of Example 2. The samples were tested according to the methods of Example 2. The samples were tested for the assays and analogs according to the specifications in Table 6.

[0070] Table 6: Shelf life of capsules of Compound I [Table 6]

[0071] Table 7: Stability data for 0.5 mg Compound I capsules (accelerated 40° C. / 75% RH) [Table 7]

[0072] Table 8: Stability data for 0.5 mg Compound I capsules (intermediate 30° C. / 65% RH) [Table 8]

[0073] Table 9: Stability data for 0.5 mg Compound I capsules (long term 25°C / 60% RH) [Table 9]

[0074] Table 10: Stability data for 1.0 mg Compound I capsules (accelerated 40° C. / 75% RH) [Table 10]

[0075] Table 11: Stability data for 1.0 mg Compound I capsules (intermediate 30° C. / 65% RH)

Table 11

[0076] Table 12: Stability data for 1.0 mg Compound I capsules (long term 25°C / 60% RH)

Table 12

[0077] Table 13: Stability data for 0.5 mg Compound IGMP Clinical Capsules (accelerated 40° C. / 75% RH)

Table 13

[0078] Table 14: Stability Data for 0.5mg Compound IGMP Clinical Capsules (Intermediate 30°C / 65%RH)

Table 14

[0079] Table 15: Stability data for 0.5 mg Compound IGMP Clinical Capsules (long term 25°C / 60% RH)

Table 15

[0080] Table 16: Stability data for 1.0 mg Compound IGMP Clinical Capsules (accelerated 40° C. / 75% RH)

Table 16

[0081] Table 17: Stability Data for 1.0 mg Compound IGMP Clinical Capsules (Intermediate 30° C. / 65% RH)

Table 17

[0082] Table 18: Stability data for 1.0 mg Compound IGMP Clinical Capsules (long term 25°C / 60% RH)

Table 18

[0083] Example 4 Table 19 below shows the chemical instability (increase in related substances over time) for PEG1500 + / - antioxidant (AO) and Gelucire 44 / 14 compared to the good stability for TPGS + AO. Table 19: Chemical instability [Table 19]

Claims

1. Dispersed in a semi-solid diluent is Compound I: [Formula 1] Compound I 1. A semi-solid pharmaceutical formulation comprising:

2. 2. The semi-solid pharmaceutical formulation of claim 1, wherein the semi-solid diluent is selected from the group comprising polyethylene glycol, water soluble surfactants, water dispersible surfactants, hard fats, vitamin E polyethylene glycol succinate, polyoxyl 35 castor oil, polyoxyl 40 castor oil, glyceryl stearate, capric / caprylic glyceryl esters and medium chain triglycerides.

3. 3. The semi-solid pharmaceutical formulation according to claim 1 or claim 2, wherein the semi-solid diluent is selected from the group comprising PEG, PEG 1000, Gelucire® 48 / 16, Gelucire® 44 / 14, Gelucire® 50 / 13, Gelucire® 43 / 01, Vitamin E polyethylene glycol succinate, Polyoxyl 35 castor oil such as Kolliphor EL, Polyoxyl 40 castor oil such as Kolliphor RH40, Solutol HS15 (polyoxyethylene ester of 12-monohydroxystearic acid), Glyceryl stearate (Imwitor 900), Capric / caprylic glyceryl esters such as Capmul MCM.

4. The semi-solid pharmaceutical formulation according to any one of claims 1 to 3, wherein the diluent is vitamin E polyethylene glycol succinate.

5. 5. The semi-solid pharmaceutical formulation according to any one of claims 1 to 4, wherein compound I is present in an amount of about 0.1% w / w to about 10% w / w.

6. 5. The semi-solid pharmaceutical formulation according to any one of claims 1 to 4, wherein compound I is present in an amount of about 0.5% w / w to about 5% w / w.

7. 5. The semi-solid pharmaceutical formulation according to any one of claims 1 to 4, wherein compound I is present in an amount of about 0.5% w / w to about 3% w / w.

8. 5. The semi-solid pharmaceutical formulation according to any one of claims 1 to 4, wherein compound I is present in an amount of about 0.05 mg to about 5 mg.

9. 5. The semi-solid pharmaceutical formulation according to any one of claims 1 to 4, wherein compound I is present in an amount of about 0.25 mg to about 2.5 mg.

10. 5. The semi-solid pharmaceutical formulation according to any one of claims 1 to 4, wherein compound I is present in an amount of about 0.5 mg to about 1 mg.

11. The pharmaceutical preparation comprises: Compound I, present in an amount of 0.5% w / w to 3% w / w; and 5. The semi-solid pharmaceutical formulation according to any one of the preceding claims, comprising Vitamin E polyethylene glycol succinate in an amount between 97% w / w and 99.5% w / w.

12. The semi-solid pharmaceutical formulation according to any one of the preceding claims, wherein the semi-solid pharmaceutical formulation is encapsulated in a gelatin capsule.

13. 1. A method for producing a semi-solid pharmaceutical formulation comprising the steps of: (i) melting a semi-solid diluent; (ii) dispersing Compound I in a molten semi-solid diluent to form a molten blend; (iii) filling the molten blend into capsule shells; The method includes:

14. 14. The method of claim 13, wherein dispersing comprises dissolving Compound I in a molten semi-solid diluent.

15. 15. The method of claim 13 or claim 14, wherein the capsule is a gelatin capsule.

16. 15. The method of claim 13 or claim 14, wherein step (i) is carried out at a temperature of about 45°C to about 80°C.

17. 17. The method according to any one of claims 13 to 16, wherein the semi-solid diluent is selected from the group comprising polyethylene glycol, water soluble surfactants, water dispersible surfactants, hard fats, vitamin E polyethylene glycol succinate, polyoxyl 35 castor oil, polyoxyl 40 castor oil, glyceryl stearate, capric / caprylic glyceryl esters and medium chain triglycerides.

18. 17. The method according to any one of claims 13 to 16, wherein the semi-solid diluent is selected from the group comprising PEG, PEG 1000, Gelucire® 48 / 16, Gelucire® 44 / 14, Gelucire® 50 / 13, Gelucire® 43 / 01, Vitamin E polyethylene glycol succinate, Polyoxyl 35 castor oil such as Kolliphor EL, Polyoxyl 40 castor oil such as Kolliphor RH40, Solutol HS15 (polyoxyethylene ester of 12-monohydroxystearic acid), Glyceryl stearate (Imwitor 900), Capric / caprylic glyceryl esters such as Capmul MCM.

19. The method according to any one of claims 13 to 16, wherein the semi-solid diluent is selected from vitamin E polyethylene glycol succinate and Gelucire® 44 / 14.

20. 20. The method according to any one of claims 13 to 19, wherein compound I is present in an amount between 0.1% w / w and 10% w / w.

21. 21. The method of claim 20, wherein compound I is present in an amount of 0.5% w / w to 3% w / w.

22. 21. The method of claim 20, wherein compound I is present in an amount of 1% w / w to 2% w / w.

23. 23. The method of any one of claims 13 to 22, wherein compound I is present in an amount of about 0.05 mg to about 5 mg.

24. 24. The method of claim 23, wherein Compound I is present in an amount of about 0.25 mg to about 2.5 mg.

25. 16. The method of any one of claims 13 to 15, wherein step (i) is carried out at a temperature of about 45°C to about 80°C, the semi-solid diluent is vitamin E polyethylene glycol succinate; and compound I is dissolved in an amount of 0.5% w / w to 3% w / w.

26. A pharmaceutical formulation according to any one of claims 1 to 12 for use as a medicament.

27. A pharmaceutical formulation according to any one of claims 1 to 12 for use in the treatment of cancer.

28. 28. The pharmaceutical formulation of claim 27, wherein the cancer is a solid tumor.

29. 28. The pharmaceutical formulation for use according to claim 27, wherein the cancer is selected from gastric cancer, thymic cancer, pancreatic cancer, and biliary tract cancer.